Clinical Trial Update: Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents [Phase 3]

View source ↗

Summary

Phase 3 study evaluating ONZETRA Xsail for acute treatment of episodic migraine in adolescents was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• ONZETRA XSAIL (Sumatriptan succinate)

Snippet

Sponsor: Currax Pharmaceuticals | Conditions: Acute Migraine With or Without Aura | Phase 3 | Status: TERMINATED | Results posted: 2023-07-24